HC Wainwright Issues Pessimistic Forecast for Aligos Therapeutics (NASDAQ:ALGS) Stock Price

Aligos Therapeutics (NASDAQ:ALGS) had its price objective reduced by HC Wainwright from $75.00 to $70.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Aligos Therapeutics Stock Performance

Shares of NASDAQ ALGS opened at $10.81 on Tuesday. The firm’s 50 day moving average price is $25.48 and its 200-day moving average price is $20.46. The company has a market cap of $38.79 million, a PE ratio of -0.81 and a beta of 2.52. Aligos Therapeutics has a 52-week low of $6.76 and a 52-week high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Monday, March 10th. The company reported ($13.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.63) by ($10.45). The company had revenue of $0.63 million for the quarter, compared to the consensus estimate of $0.43 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same quarter last year, the company earned ($5.50) EPS. On average, analysts forecast that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its position in Aligos Therapeutics by 2,073.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock valued at $26,000 after purchasing an additional 622 shares during the period. AlphaMark Advisors LLC lifted its position in Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after purchasing an additional 1,000 shares during the period. Golden State Wealth Management LLC bought a new position in Aligos Therapeutics during the fourth quarter valued at approximately $107,000. Northern Trust Corp bought a new position in Aligos Therapeutics during the fourth quarter valued at approximately $205,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Aligos Therapeutics by 19.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock valued at $569,000 after buying an additional 2,306 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).